Skip to main content

Signed · Germany · Pharma and biotech

Telix agrees to acquire ITM.

Telix Pharmaceuticals, based in Melbourne, Australia, signed a share purchase agreement on 21 September 2026 to acquire all shares of ITM Isotope Technologies Munich SE, a radiopharmaceutical company headquartered in Munich, Germany. Part of the price is paid in new Telix shares, and ITM shareholders would hold about 23.7 percent of Telix on completion. It was signed on 21 September 2026. It had not completed by 28 October 2026.

SigningDay 100

Signing 21 September 2026

Buyer
Telix Pharmaceuticals Limited ·Melbourne, Australia
Target
ITM Isotope Technologies Munich SE ·Munich, Germany
Type
Acquisition
Announced
21 September 2026
Signed
21 September 2026
Value
USD 1.65 billion upfront (cash-free, debt-free) plus conting
People
Not stated in the release
Last checked
28 October 2026

The people side in Germany

Get the briefing

Deals into Europe lists public facts with their sources, checked every working day by Octagon Professionals International. Corrections go to info@octagon.nl and are made within one working day. How we track deals.

Enabling organisations to operate across borders with clarity, compliance, and trust.

All deals into Europe